What is the mechanism of action of GHK-Cu?

GHK chelates copper(II) and acts as a transcriptional modulator: published microarray data show it influences over 4,000 human genes including resetting expression patterns toward younger cellular phenotypes. Strongly upregulates collagen, elastin, and proteoglycan synthesis. Promotes angiogenesis and macrophage recruitment in wound beds. For scheduling and cycle applications specifically, the relevant downstream consequence is the cascade from receptor engagement to systemic effect: GHK chelates copper(II) and acts as a transcriptional modulator: published microarray data show it influences over 4,000 human genes including resetting expression patterns toward younger cellular phenotypes. The protocol / scheduling / cycling interpretation focuses on the pathway-level detail rather than on any single high-level summary.

How should GHK-Cu be stored and reconstituted?

Lyophilised GHK-Cu stores at −20°C for 18–24 months. After reconstitution with bacteriostatic water, the solution holds at 4°C for 14–28 days. Avoid freeze-thaw cycles of reconstituted material. Travel with cold packs in insulated containers; avoid prolonged exposure above 25°C. The standard reconstitution concentration is 1–2 mg/mL depending on the vial size.

What route should I use for GHK-Cu?

GHK-Cu is delivered by subq/topical/oral. The oral route engages enteric receptors and the gut-brain axis directly. The choice depends on target system and convenience.

How do I schedule GHK-Cu alongside my existing stack?

GHK-Cu's schedule is built around its ~30 min plasma pharmacokinetics and 1x daily (subq); topical formulations vary dosing pattern. Coordination with other peptides depends on route compatibility (multiple SubQ compounds can share an injection where chemistry permits), receptor overlap (avoid stacking compounds engaging the same primary receptor), and operational convenience. Add one new compound at a time with 2 weeks of isolated dosing before stacking.

Home/ Compounds/ GHK-Cu

GHK-Cu

Protocol

Scheduling GHK-Cu alongside existing protocols, training, and lifestyle inputs requires understanding the compound's pharmacokinetic constraints and the cycle calendar. A naturally occurring tripeptide-copper complex that declines with age and is studied for its broad effects on wound healing, skin remodelling, and gene expression. Daily timing relative to meals and training, weekly cycle structure, and integration with stack components on independent pathways are the three layers of the protocol calendar developed below.

Protocol / Scheduling / Cycling Applications

Tapered CyclesCycle LengthLoading PhaseMulti-Peptide TimingDaily Timing

Key Takeaways

Scheduling lens: GHK-Cu's ~30 min plasma half-life via subq/topical/oral places it in the multi-daily-dosing bucket.
Mechanism: GHK chelates copper(II) and acts as a transcriptional modulator: published microarray data show it influences over 4,000 human genes including resetting expression patterns toward younger cellular phenotypes.
Cycle structure: 8-12 weeks on, 4 weeks off; the off-period is functionally required for receptor reset.
Stack scheduling: add one compound at a time with 2 weeks of isolated dosing before layering.
Schedule-compatible stack partners: BPC-157, TB-500, Ipamorelin.

Protocol / Scheduling / Cycling Mechanism

GHK chelates copper(II) and acts as a transcriptional modulator: published microarray data show it influences over 4,000 human genes including resetting expression patterns toward younger cellular phenotypes. Strongly upregulates collagen, elastin, and proteoglycan synthesis. Promotes angiogenesis and macrophage recruitment in wound beds. The scheduling implications cascade from this mechanism: receptor occupancy curves dictate daily timing, downregulation kinetics dictate cycle length, route compatibility dictates stack scheduling. The subsections address each in turn for GHK-Cu.

Daily and weekly timing

GHK-Cu with a ~30 min plasma half-life pharmacokinetic profile sits in the daily-dosing bucket. The schedule is best built around either 1x daily (SubQ); topical formulations vary, with consistency mattering more than the absolute clock time of any single dose.

Travel, schedule shifts, and continuity

Maintaining cycle continuity through travel, time-zone shifts, and irregular schedules is one of the practical considerations for any GHK-Cu protocol. Cold-chain requirements (where applicable), customs considerations for international travel, and adjustment for time-zone shifts within a 24–48 hour window are the main operational issues. For most GHK-Cu schedules a ±8-hour timing shift has no clinical effect; longer shifts warrant minor schedule adjustment.

Stack scheduling with other compounds

When GHK-Cu is part of a multi-compound stack, the scheduling question becomes how to time its dose relative to the others. Oral and subcutaneous compounds can be timed independently; the routes do not interact. The pragmatic schedule reflects both pharmacokinetic constraints and the user's operational reality.

Protocol / Scheduling / Cycling Applications

Cycle Design

Schedule design for GHK-Cu in cycle design starts from pharmacokinetic constraints: less frequent dosing for long half-life compounds. The cycle length and off-period are then layered on top of the daily schedule.

Off-Time

The most-asked scheduling question for GHK-Cu in off-time is when to time doses relative to meals and training. The general principle: fasted dosing for compounds engaging the GH axis or AMPK; meal-paired dosing for incretins; flexibility for compounds whose pharmacokinetics permit it.

Multi-Peptide Timing

For multi-peptide timing scheduling, GHK-Cu is best run in 8–12 week cycles with 4 week off-periods. Daily timing within the cycle is calibrated to pharmacokinetics; weekly timing is calibrated to training and lifestyle constraints. The schedule is the protocol.

Cycle Length

Schedule design for GHK-Cu in cycle length starts from pharmacokinetic constraints: less frequent dosing for long half-life compounds. The cycle length and off-period are then layered on top of the daily schedule.

Dosing Protocol

Goal	Route	Dose	Cycle
Standard protocol	SubQ	1-2 mg	8–12 weeks on / 4 weeks off
Conservative starter	SubQ	1-2 mg	4–6 weeks initial cycle
Protocol focus	SubQ	1-2 mg	1x daily (SubQ); topical formulations vary
Maintenance phase	SubQ	1-2 mg	Ongoing with periodic pauses

Dose timing for GHK-Cu is important relative to food and training given the short half-life. Consistency through the cycle is more important than the precise clock time of individual doses.

Stacking

GHK-Cu stacks well with compounds on complementary pathways. The pairings below are the conventional combinations from protocol designers.

GHK-Cu + BPC-157: Upregulates VEGFR2 to promote angiogenesis and activates the FAK-paxillin pathway for accelerated tissue repair. Pairs naturally with GHK-Cu's mechanism in protocol / scheduling / cycling protocols.
GHK-Cu + TB-500: Binds G-actin monomers and prevents their incorporation into F-actin filaments, regulating the cellular actin pool. Pairs naturally with GHK-Cu's mechanism in protocol / scheduling / cycling protocols.
GHK-Cu + Ipamorelin: Highly selective GHSR1a agonist. Pairs naturally with GHK-Cu's mechanism in protocol / scheduling / cycling protocols.
GHK-Cu + CJC-1295 without DAC (Mod GRF 1-29): Same GHRH-receptor agonism as DAC variant. Pairs naturally with GHK-Cu's mechanism in protocol / scheduling / cycling protocols.

Safety & Regulatory Status

WADA: Not on prohibited list FDA: Topical cosmetic use; injectable unapproved Research: Decades of human data on skin and wound healing

Excellent tolerability via all routes. Mild bluish discolouration at injection site possible (copper).

Lens-specific safety considerations for protocol / scheduling / cycling use of GHK-Cu: Excellent tolerability via all routes. Mild bluish discolouration at injection site possible (copper). Additional protocol / scheduling / cycling monitoring at baseline and 6–8 week follow-up is appropriate.

Clinical Evidence

Primary

GHK-Cu — DNA repair and gene modulation

PMID 22593585

Supporting

Possible therapeutic effects of adding the tripeptide GHK to cosmetics

PMID 22928089

GHK-Cu vs Related Peptides

Compound	Profile	Onset	Best For
GHK-Cu	Tripeptide-copper complex	~30 min plasma	Protocol
BPC-157	Stable gastric pentadecapeptide	~4 hr (oral)	Accelerated tendon, ligament, and gut tissue repair via VEGFR2-driven angiogenesis and FAK-paxillin signalling
TB-500	Synthetic thymosin β4 fragment	~2-3 days	A 17-amino-acid synthetic fragment of thymosin β4 with actin-sequestering activity — drives cell migration, tissue repair, and broad regenerative effects
Ipamorelin	Selective GHRP / ghrelin mimetic	~2 hr	The most selective ghrelin-receptor agonist among the GHRPs — stimulates GH release with minimal effect on cortisol, prolactin, or appetite

Frequently Asked Questions

Cycle length and off-cycle period?

Standard cycle for GHK-Cu is 8–12 weeks on, 4 weeks off. Longer cycles produce diminishing returns and increased downregulation risk; shorter cycles undershoot the response window. The 4-week off-period is functionally required for receptor reset rather than optional.

When to integrate GHK-Cu into an existing stack?

Add one new compound at a time, with at least 2 weeks of isolated dosing to establish individual response, before layering additional compounds. This approach prevents stack complexity from masking individual contributions and makes troubleshooting tractable.

Daily timing for GHK-Cu?

Pragmatic timing depends on pharmacokinetics: multi-daily dosing for short half-life. Consistent timing matters more than the absolute clock time of any single dose.

Best practice for re-cycling?

Run baseline labs before each cycle. Compare to prior cycle. Adjust dose downward if response is maintained; adjust upward only if response is incomplete and labs support the safety margin. Long-term cycle records inform protocol drift over years.

Should I cycle GHK-Cu?

Standard cycle for GHK-Cu is 8–12 weeks of 1x daily (subq); topical formulations vary 1-2 mg dosing via subq/topical/oral, followed by a 4 week complete off-period. The off-period is calibrated to GHK-Cu's ~30 min plasma half-life and to typical receptor downregulation timelines. Continuous indefinite dosing does not show additional clinical benefit in the published literature and increases cumulative downregulation risk.

What is the regulatory status of GHK-Cu?

GHK-Cu regulatory status: Topical cosmetic use; injectable unapproved in the United States; WADA status not on prohibited list; research level decades of human data on skin and wound healing. Clinical access for off-label use is via compounded prescription where permissible. International regulatory status varies by jurisdiction. For scheduling and cycle use specifically, the regulatory profile shapes which monitoring and supervision approaches are required.

Clinical Protocol

Start a GHK-Cu Protocol

Alukard provides physician-supervised peptide protocols with GMP-certified GHK-Cu and GMP-certified compounds with personalised cycle design.

Get Protocol

Quick Facts

Molecular weight: 402 Da (copper-bound)
Sequence length: 3 aa
Half-life: ~30 min plasma
WADA: Not on prohibited list
FDA: Topical cosmetic use; injectable unapproved
Research: Decades of human data on skin and wound healing

Stack Partners

BPC-157

TB-500

Ipamorelin

CJC-1295 without DAC (Mod GRF 1-29)

Semax

Research Note

All protocol / scheduling / cycling applications described on this page are derived from preclinical research, animal models, and limited human case data. None of these uses are FDA-approved indications for GHK-Cu unless otherwise noted. Always work with a physician familiar with peptide therapeutics before beginning a protocol.

Physician-supervised peptide protocols

Start Your Protocol / Scheduling / Cycling Protocol for GHK-Cu

Alukard provides physician-supervised peptide protocols with GMP-certified compounds with personalised cycle design.

Get a Physician Consultation View All Compounds

HIPAA Compliant · GMP Certified · Physician Supervised